Motif XCS System for Depression

(RESONATE Trial)

This trial tests a new device called the Motif eXternally powered Cortical Stimulation (XCS) System to determine its safety and effectiveness for individuals with treatment-resistant depression. It targets those with major depressive disorder who have not found success with at least two different antidepressants. Participants should currently experience a major depressive episode and maintain a stable treatment plan. For those who have tried other therapies, such as electroconvulsive therapy or transcranial magnetic stimulation, without success, this device might offer an alternative. The researchers aim to discover new methods to assist individuals whose depression does not respond to traditional treatments. As an unphased trial, this study provides a unique opportunity to explore innovative treatments for depression.

The trial requires that you stay on a stable psychiatric treatment regimen for 30 days before the study and maintain it through the Week 4 follow-up visit. However, you cannot take ketamine, esketamine, or hallucinogenic medications 30 days before and during the trial.

Research has shown that the Motif eXternally powered Cortical Stimulation (XCS) System is safe and generally well-tolerated. One study found that this type of brain stimulation was safe and effective for teenagers with depression unresponsive to other treatments, with no major safety concerns or serious side effects reported.

The Motif eXternally powered Cortical Stimulation (XCS) System is unique because it offers a new approach to treating depression with a non-invasive brain stimulation technique. Unlike traditional antidepressants, which alter chemical balances in the brain, this system directly targets brain activity by using external electrical stimulation. Researchers are excited about this treatment because it has the potential to provide faster relief with fewer side effects compared to conventional medications. Additionally, the non-invasive nature of the device means it could be a more accessible option for those who cannot tolerate or do not respond to drugs.

Research has shown that the Motif XCS System, which participants in this trial will receive, is designed to help individuals with treatment-resistant depression (TRD) through cortical stimulation. This technique gently stimulates specific brain areas to potentially improve mood and mental health. Although detailed information about the system's effectiveness is not yet widely available, early signs suggest that similar treatments have managed severe depression in other cases. The aim is to provide an option for those who haven't found relief from other treatments. The researchers hope this method will offer a new way to ease ongoing depressive symptoms.⁶⁷⁸⁹¹⁰